Published in final edited form as:

Biomater Sci. 2016 April ; 4(4): 610–613. doi:10.1039/c5bm00514k.

Modeling the tumor microenvironment using chitosan-alginate scaffolds to control the stem-like state of glioblastoma cells

Forrest M. Kievit^a, Kui Wang^b, Ariane E. Erickson^b, Sheeny K. Lan Levensgood^b, Richard G. Ellenbogen^{a,†}, and Miqin Zhang^{a,b,†}

^aDepartment of Neurological Surgery, University of Washington, Seattle, WA 98195, USA

^bDepartment of Materials Science & Engineering, University of Washington, Seattle, WA 98195, USA

Abstract

Better prediction of *in vivo* drug efficacy using *in vitro* models should greatly improve *in vivo* success. Here we utilize 3D highly porous chitosan-alginate complex scaffolds to probe how various components of the glioblastoma microenvironment including extracellular matrix and stromal cells affect tumor cell stem-like state.

The failure of new therapies in *in vivo* and clinical trials represents a costly bottleneck for new drug development. The vast majority of cancer drug development begins with *in vitro* testing using cell lines. However, many of these therapies that show promise *in vitro* fail during *in vivo* trials. Failure can be caused by various factors such as poor biodistribution, low serum stability, high off-target toxicity, and lower efficacy in cancer cells growing as part of the larger tumor microenvironment. The ability to better predict *in vivo* drug efficacy *in vitro* could rapidly accelerate novel drug development and reduce costs associated with these animal experiments.¹

We have developed 3D highly porous scaffolds of polyelectrolyte chitosan-alginate (CA) complexes for *in vitro* culture of cancer cells that better mimic the behavior of cells growing as part of a tumor than cells culture on 2D well plates.² We have shown that culturing cancer cells in these scaffolds drastically alters their growth, shape, and gene expression profile towards being more malignant. Indeed, we have shown enrichment of the cancer stem-like cell population indicating the more aggressive phenotype of cells cultured on these scaffolds, which was attributed to the 3D chemical extracellular matrix (ECM) environment afforded by the scaffolds.³ However, the tumor microenvironment comprises not only ECM but contains a variety of stromal cells that can both affect tumor growth, progression, and stem-like state.⁴ In fact, the tumor microenvironment has recently received significant attention in the development of new anti-cancer therapies.^{4b, 5} Therefore, the ability to model, *in vitro*, how the various parts of the tumor microenvironment affect tumor behavior could greatly

[†]Corresponding authors: mzhang@uw.edu. Phone: (206) 616-9356. M. Zhang, rge@uw.edu. Phone: (206) 744-9321. R. G. Ellenbogen.

Electronic Supplementary Information (ESI) available: Detailed methods and low magnification images of tumor spheres growing in scaffolds. See DOI: 10.1039/x0xx00000x

accelerate the development of these next-generation therapies. Our CA scaffolds are well suited to systematically test how each stromal compartment affects cancer cell behavior.

Here we aim to utilize our CA scaffolds to probe how the tumor microenvironment of glioblastoma (GBM), the most common and deadly brain cancer, affects their growth and malignancy. We test how differences in extracellular composition and stromal cell type affect the stem-like properties of GBM cells. CA scaffolds were coated with hyaluronic acid (HA), a major ECM protein in GBM,⁶ or polycaprolactone (PCL) as a control to block the chemical structure of the CA scaffold so that only the 3D environment was present. GBM cells were also co-cultured in scaffolds with the primary stromal cells of GBM, astrocytes and endothelial cells.⁷ The effects of these changes in the tumor microenvironment on GBM cells were analyzed through protein and gene expression analyses.

CA scaffolds were coated with PCL as reported previously³ to generate PCL-CA scaffolds, and coated with HA following a similar procedure to generate HA-CA scaffolds. HA was dissolved in acetic acid at 0.5% and then diluted in methanol to 0.05%. Scaffolds were added to the HA solution and allowed to coat for 4 hrs before quickly drying with an air gun, sterilized with 70% ethanol overnight, and then washed with PBS before use. HA coating was confirmed with FTIR (Fig. 1b). A unique characteristic peak at 1380 cm^{-1} from HA was observed in HA-CA scaffolds (Fig. S1) indicating HA present on the scaffolds. The presence of PCL was observed from the unique characteristic peak at 1750 cm^{-1} . To ensure pore structure was not altered, scaffolds were imaged using SEM (Fig. 1a). Pore structure remained similar to uncoated CA scaffolds as determined from low magnification images. High magnification images show the uniform coating of PCL or HA on the surface of the scaffold walls.

Cells (red fluorescent protein (RFP) expressing U-87 MG) were seeded (50,000 in 50 μL) on optimized coated scaffolds (uncoated, PCL, HA) and imaged over 8 days. Cells cultured in uncoated CA scaffolds showed similar growth as seen previously,^{2b, 3} generating $\sim 40\text{ }\mu\text{m}$ diameter tumor spheres within the scaffold in 8 days (Figure 2). Cells cultured in HA-CA scaffolds showed similar growth trend, but the number of tumor spheres within the scaffold was much more numerous (Fig. S2). Cells cultured in PCL-CA scaffolds displayed a more elongated structure similar to that seen with 2D culture, and no tumor spheres were observed in the lower magnification images (Fig. S2).

On day 10, cells were imaged and collected for SEM, Western blot, and PCR analyses. SEM imaging confirmed that the cell structure observed with fluorescence imaging tumor spheroids in the CA and HA-CA scaffolds and elongated cells in the PCL-CA scaffolds (Fig. 3a–b). Western blot was used to detect expression of CD44 and Id1 (Fig. S3), whose increased expressions suggest an increase in the stem-like cell state of the cells.⁸ Fig. 3c shows an increase in expression of both CD44 and Id1 protein in cells cultured in HA-CA scaffolds suggesting cells on these scaffolds were more stem-like. CD44 is the cell surface receptor for HA so is likely upregulated in response to HA present on the scaffold. Overexpression of Id1, an inhibitor of DNA binding protein involved in regulation of self-renewal in neural stem cells⁹ and cancer metastases,¹⁰ in combination with CD44 is thought to represent a stem-like population of GBM cells.¹¹ To further assess the stem-like

characteristics of these cells, expression of the cancer stem-like cell gene *CD133*¹² was assessed using PCR (Fig. 3d) to avoid confusing glycosylated and non-glycosylated forms of CD133 protein in Western blots.¹³ CD133+ GBM subpopulations are well characterized to be enriched in cancer stem-like cells.^{12b, 14} Cells cultured in HA-CA scaffolds showed a 3.5-fold increase in *CD133* expression, nearly double that observed in cells cultured in CA scaffolds. This suggests that changing the chemical microenvironment altered the cancer stem-like properties of cultured GBM cells.

The most common stromal cells present in GBM are endothelial cells and astrocytes.⁷ These cells have been shown to provide a niche for GBM stem-like cells to invade surrounding brain¹⁵ and promote drug resistance.^{7a, 16} For co-culture experiments, U-87 MG cells were mixed at various ratios with human astrocytes or endothelial cells (HUVEC) prior to seeded on scaffolds. Ratios between stromal:tumor cells were 1:5, 1:1, and 5:1 with 50,000 U-87 MG cells seeded in each scaffold. The growth behavior of the cells was visualized through live cell fluorescence imaging using RFP expressing U-87 MG cells and stromal cells labeled with green Vybrant CFDA SE Cell Tracer dye at 10 μ M following the manufacturer's protocol, which gave visible fluorescence over 10 days without observable toxicity to the cells (data not shown).

Co-culture with either astrocytes or HUVECs resulted in smaller tumor spheres forming (Fig. S4) suggesting a slower growth rate of the tumor cells (Fig. 4). Tumor spheres were observed to form around or on the stromal cells, which grew significantly slower, so final tumor sphere had only one to a few stromal cells associated with them. The lower ratio of stromal cell to tumor cell showed similar tumor sphere sizes to tumor cells grown without stromal cells likely because of the minimal number of tumor cells that had a stromal cell to incorporate with.

Western blot revealed an increased expression of CD44 and Id1 (Fig. S5) with increased ratios of astrocytes or HUVECs to U-87 MG cells (Fig. 5a–b). Additionally, this increase was accompanied by increased CD133 mRNA abundance (Fig. 5c) suggesting co-culture with stromal cells increased the stem-like properties of U-87 MG cells. This is in accordance with the smaller tumor spheres observed at higher stroma:tumor cell ratios, since the slower growth of tumor cells may suggest reversion to a more stem-like state rather than simply uncontrolled cell proliferation, which we've observed previously.^{3, 17} The slower growth of tumor spheres combined with the increased expression of stem-like cancer cell markers provides strong evidence that we can finely adjust the tumor microenvironment *in vitro* to better mimic *in vivo* conditions.

In conclusion, we showed that altering the tumor microenvironment *in vitro* alters the expression of glioblastoma stem-like cell markers. This correlates well with the growing body of evidence that the stromal compartment plays a significant role in tumor aggressiveness and progression, and that this can be modeled *in vitro*. We found that both the chemical structure of the microenvironment and the presence of stromal cells impact glioblastoma stem-like cell state. We hope these modified scaffolds will be used to further probe how each stromal compartment affects tumor behavior in order to accelerate the development of more effective cancer therapies.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by NIH grant R01CA172455. F.K. acknowledges support from an American Brain Tumor Association Fellowship in Honor of Susan Kramer, K.W. acknowledges support from the University of Washington College of Engineering Dean's Fellowship, and A.E. acknowledges support from the National Science Foundation Graduate Research Fellowship. We acknowledge the use of the SEM at the University of Washington Center for Nanotechnology. We acknowledge laboratory assistance from Ms. Anna A. Thompson and Ms. Melanie J. Coyne for running Western blots.

Notes and references

1. Hutmacher DW. Nature materials. 2010; 9:90. [PubMed: 20094076]
2. (a) Florczyk SJ, Liu G, Kievit FM, Lewis AM, Wu JD, Zhang M. Advanced healthcare materials. 2012; 1:590. [PubMed: 23184794] (b) Kievit FM, Florczyk SJ, Leung MC, Veiseh O, Park JO, Disis ML, Zhang M. Biomaterials. 2010; 31:5903. [PubMed: 20417555] (c) Leung M, Kievit FM, Florczyk SJ, Veiseh O, Wu J, Park JO, Zhang M. Pharm Res. 2010; 27:1939. [PubMed: 20585843] (d) Florczyk SJ, Kim DJ, Wood DL, Zhang M. J Biomed Mater Res A. 2011; 98:614. [PubMed: 21721118]
3. Kievit FM, Florczyk SJ, Leung MC, Wang K, Wu JD, Silber JR, Ellenbogen RG, Lee JS, Zhang M. Biomaterials. 2014; 35:9137. [PubMed: 25109438]
4. (a) Junttila MR, de Sauvage FJ. Nature. 2013; 501:346. [PubMed: 24048067] (b) Hanahan D, Weinberg RA. Cell. 2011; 144:646. [PubMed: 21376230]
5. (a) Quail DF, Joyce JA. Nat Med. 2013; 19:1423. [PubMed: 24202395] (b) Jain RK. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013; 31:2205. [PubMed: 23669226]
6. (a) Ananthanarayanan B, Kim Y, Kumar S. Biomaterials. 2011; 32:7913. [PubMed: 21820737] (b) Toole BP. Nat Rev Cancer. 2004; 4:528. [PubMed: 15229478]
7. (a) Golebiewska A, Bougnaud S, Stieber D, Brons NHC, Vallar L, Hertel F, Klink B, Schrock E, Bjerkvig R, Niclou SP. Brain. 2013; 136:1462. [PubMed: 23460667] (b) Rath BH, Fair JM, Jamal M, Camphausen K, Tofilon PJ. PLoS One. 2013; 8:e54752. [PubMed: 23349962]
8. Pietras A, Katz AM, Ekstrom EJ, Wee B, Halliday JJ, Pitter KL, Werbeck JL, Amankulor NM, Huse JT, Holland EC. Cell Stem Cell. 2014; 14:357. [PubMed: 24607407]
9. Nam HS, Benezra R. Cell Stem Cell. 2009; 5:515. [PubMed: 19896442]
10. Gupta GP, Perk J, Acharyya S, de Candia P, Mittal V, Todorova-Manova K, Gerald WL, Brogi E, Benezra R, Massague J. Proc Natl Acad Sci U S A. 2007; 104:19506. [PubMed: 18048329]
11. Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA, Prieto-Sanchez RM, Barba I, Martinez-Saez E, Prudkin L, Cuatras I, Raventos C, Martinez-Ricarte F, Poca MA, Garcia-Dorado D, Lahn MM, Yingling JM, Rodon J, Sahuquillo J, Baselga J, Seoane J. Cancer Cell. 2010; 18:655. [PubMed: 21156287]
12. (a) Lathia JD, Hitomi M, Gallagher J, Gadani SP, Adkins J, Vasanji A, Liu L, Eyler CE, Heddleston JM, Wu Q, Minhas S, Soeda A, Hoepfner DJ, Ravin R, McKay RD, McLendon RE, Corbeil D, Chenn A, Hjelmeland AB, Park DM, Rich JN. Cell Death Dis. 2011; 2:e200. [PubMed: 21881602] (b) Tirino V, Desiderio V, d'Aquino R, De Francesco F, Pirozzi G, Graziano A, Galderisi U, Cavaliere C, De Rosa A, Papaccio G, Giordano A. PLoS One. 2008; 3:e3469. [PubMed: 18941626] (c) Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Nature. 2004; 432:396. [PubMed: 15549107]
13. (a) Osmond TL, Broadley KW, McConnell MJ. Int J Mol Med. 2010; 25:883. [PubMed: 20428792] (b) Bidlingmaier S, Zhu X, Liu B. J Mol Med (Berl). 2008; 86:1025. [PubMed: 18535813] (c) Hermansen SK, Christensen KG, Jensen SS, Kristensen BW. J Histochem Cytochem. 2011; 59:391. [PubMed: 21411810]

14. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. *Nature*. 2006; 444:756. [PubMed: 17051156]
15. (a) Grodecki J, Short AR, Winter JO, Rao SS, Winter JO, Otero JJ, Lannutti JJ, Sarkar A. *Biotechnology progress*. 2015(b) Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ. *Cancer Cell*. 2007; 11:69. [PubMed: 17222791]
16. Yang N, Yan T, Zhu H, Liang X, Leiss L, Sakariassen PO, Skafnesmo KO, Huang B, Costea DE, Enger PO, Li X, Wang J. *Journal of translational medicine*. 2014; 12:278. [PubMed: 25280402]
17. Florczyk SJ, Wang K, Jana S, Wood DL, Sytsma SK, Sham JG, Kievit FM, Zhang M. *Biomaterials*. 2013; 34:10143. [PubMed: 24075410]

Figure 1. Scaffold characterization. a) SEM images of scaffolds with different coatings showing pore structure at low magnification and wall structure at high magnification. Scale bars for low and high magnification correspond to 500 μm and 20 μm , respectively. b) FTIR characterization indicating the presence of HA or PCL on the scaffolds.

Figure 2.

Fluorescence images of U-87 MG cells cultured on coated and uncoated CA scaffolds for 8 days. Scale bar corresponds to 20 μm .

Figure 3.

U-87 MG cells cultured in different scaffolds for 10 days. a) Fluorescence images of cells cultured in different scaffolds indicating their morphology. The scale bar corresponds to 20 μ m. b) Colorized SEM images confirming morphology. Cells were identified and pseudocolored in Photoshop. The scale bar corresponds to 20 μ m. c) Differential expression of CD44 and Id1 protein in U-87 MG cells cultured in different scaffolds as determined by Western blot. Band densities were normalized to β -actin and 2D culture. d) Differential CD133 mRNA abundance in U-87 MG cells cultured in different scaffolds as determined by PCR. β -actin was used as the reference gene and mRNA abundance was normalized to 2D culture. ** indicates a statistical difference from CA culture as determined by Student's t test ($p < 0.001$).

Figure 4.

Fluorescence images of U-87 MG cells cultured on CA scaffolds with human astrocytes or HUVEC cells for 10 days. Scale bar corresponds to 20 μm . U-87 MG cells are red and stromal cells are green.

Figure 5.

Cancer stem-like cell (CSC) gene expression analysis after 10-day culture of U-87 MG cells in CA scaffolds with different stromal cells. a) Western blot analysis of CD44. b) Western blot analysis of Id1. c) PCR analysis of CD133. Data is normalized to cells cultured on 2D. The U87 label represents U-87 MG cells cultured on CA scaffolds without stromal cells. Statistical significance was determined by Student's t test (* indicates $p < 0.01$).